ScoreWhy is Shanxi C&Y Pharmaceutical Group Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 2.56%
- The company has been able to generate a Return on Capital Employed (avg) of 2.56% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -3.32% and Operating profit at 20.11% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 7.73% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of -3.32% and Operating profit at 20.11% over the last 5 years
4
Negative results in Mar 25
- NET PROFIT(HY) At CNY 8.43 MM has Grown at -86.26%
- INTEREST COVERAGE RATIO(Q) Lowest at 235.77
- DEBT-EQUITY RATIO (HY) Highest at 234.87 %
5
With ROE of 16.56%, it has a very expensive valuation with a 5.63 Price to Book Value
- Over the past year, while the stock has generated a return of 7.83%, its profits have fallen by -64.9%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Shanxi C&Y Pharmaceutical Group Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shanxi C&Y Pharmaceutical Group Co., Ltd.
6.7%
0.69
45.54%
China Shanghai Composite
14.77%
1.01
15.10%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-3.32%
EBIT Growth (5y)
20.11%
EBIT to Interest (avg)
-0.09
Debt to EBITDA (avg)
9.89
Net Debt to Equity (avg)
1.37
Sales to Capital Employed (avg)
0.88
Tax Ratio
10.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.56%
ROE (avg)
7.73%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
5.63
EV to EBIT
32.37
EV to EBITDA
15.49
EV to Capital Employed
2.84
EV to Sales
2.24
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
8.78%
ROE (Latest)
16.56%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -13.12% (YoY
-24What is not working for the Company
NET PROFIT(HY)
At CNY 8.43 MM has Grown at -86.26%
INTEREST COVERAGE RATIO(Q)
Lowest at 235.77
DEBT-EQUITY RATIO
(HY)
Highest at 234.87 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 2.17%
DEBTORS TURNOVER RATIO(HY)
Lowest at 5.31%
NET SALES(Q)
Lowest at CNY 179.4 MM
INTEREST(Q)
Highest at CNY 5.95 MM
OPERATING PROFIT(Q)
Lowest at CNY 14.02 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 7.81 %
Here's what is working for Shanxi C&Y Pharmaceutical Group Co., Ltd.
Raw Material Cost
Fallen by -13.12% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Shanxi C&Y Pharmaceutical Group Co., Ltd.
Net Profit
At CNY 8.43 MM has Grown at -86.26%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (CNY MM)
Net Sales
At CNY 179.4 MM has Fallen at -14.09%
over average net sales of the previous four periods of CNY 208.81 MMMOJO Watch
Near term sales trend is very negative
Net Sales (CNY MM)
Interest
At CNY 5.95 MM has Grown at 28.2%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Interest Coverage Ratio
Lowest at 235.77
in the last five periodsMOJO Watch
The company's ability to manage interest payments is deteriorating
Operating Profit to Interest
Net Sales
Lowest at CNY 179.4 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Interest
Highest at CNY 5.95 MM
in the last five periods and Increased by 28.2% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Operating Profit
Lowest at CNY 14.02 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CNY MM)
Operating Profit Margin
Lowest at 7.81 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Debt-Equity Ratio
Highest at 234.87 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 2.17%
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 5.31%
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
